Table 3.
Parameters of CWA-TT in PPP from healthy volunteers, patients with solid cancer, and patients with malignancy.
| 2nd DPT (seconds) |
2nd DPH (mm ABS) |
1st DPT-1 (seconds) |
1st DPH-1 (mm ABS) |
1st DPT-2 (seconds) |
1st DPH-2 (mm ABS) |
FFCT (seconds) |
FFCH (mm ABS) |
|
|---|---|---|---|---|---|---|---|---|
| Healthy volunteers (n = 18) | 30.5 (28.9–30.9) |
164 (137–219) |
36.3 (35.0–37.5) |
113 (96.5–132) |
234 (220–278) |
18.1 (15.4–22.9) |
194 (185–204) |
615 (560–664) |
| Thrombocytopenia (n = 12) | 34.9 * (31.0–39.2) |
143 (78.5–255) |
43.2 * (37.6–47.5) |
106 * (70.2–157) |
Not detectable |
Not detectable |
202 (152–209) |
550 (492–637) |
| Malignant diseases (n = 16) |
30.3 (28.6–46.1) |
321 * (137–420) |
35.0 (33.7–52.7) |
166 *** (103–207) |
228 (173–273) |
28.5 ** (21.6–43.3) |
187 (157–236) |
738 ** (656–874) |
Data are shown as the median (25–75 percentile). ***, p < 0.001, **, p < 0.01; *, p < 0.05 compared with healthy volunteers. PPP, platelet-poor plasma; 2nd DPT, second derivative peak time; 2nd DPH, second derivative peak height; 1st DPT, first derivative peak time; 1st DPH, first derivative peak height, FFCT, fibrin formation curve time; FFCH, fibrin formation curve height; ABS, absorbance.